1. Home
  2. GSL vs MPLT Comparison

GSL vs MPLT Comparison

Compare GSL & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GSL

Global Ship Lease Inc New

HOLD

Current Price

$41.84

Market Cap

1.5B

ML Signal

HOLD

Logo MapLight Therapeutics Inc.

MPLT

MapLight Therapeutics Inc.

HOLD

Current Price

$12.28

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GSL
MPLT
Founded
2007
2018
Country
Greece
United States
Employees
7
133
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.7B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
GSL
MPLT
Price
$41.84
$12.28
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
7
Target Price
$44.00
$32.67
AVG Volume (30 Days)
304.3K
1.3M
Earning Date
05-18-2026
05-28-2026
Dividend Yield
6.34%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$3.49
N/A
Revenue Growth
N/A
N/A
52 Week Low
$27.28
$9.10
52 Week High
$44.69
$40.43

Technical Indicators

Market Signals
Indicator
GSL
MPLT
Relative Strength Index (RSI) 49.23 28.72
Support Level $37.00 $11.56
Resistance Level $42.70 $20.73
Average True Range (ATR) 1.10 2.03
MACD -0.26 -1.11
Stochastic Oscillator 3.93 11.12

Price Performance

Historical Comparison
GSL
MPLT

About GSL Global Ship Lease Inc New

Global Ship Lease Inc is a containership owner, leasing ships to container shipping companies under industry-standard, fixed-rate time charters. Its fleet comprises mid-size Post-Panamax, Cypress, and smaller containerships, which tend to serve the faster-growing non-Mainlane and intra-regional trades, collectively representing the majority of the containerized trade volume globally. The company generates revenue from chartering its vessels to liner companies.

About MPLT MapLight Therapeutics Inc.

MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.

Share on Social Networks: